Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compugen has entered into collaboration with Merck & Co., Whitehouse Station, New Jersey, targeted at predicting peptides likely to activate selected G-protein coupled receptors and validating their agonistic activity.
Subscribe to our email newsletter
The agreement includes an option to Merck for exclusive worldwide licenses for such peptides – on a peptide by peptide basis – covering the development and commercialization of therapeutic products.
Alex Kotzer, president and CEO of Compugen, said: “We are very pleased that our first collaboration based on this capability is with Merck, one of the world’s leading research-based pharmaceutical companies.”